Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesa Laboratories, Inc. (MLAB) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Mesa is a Colorado corporation whose common stock is listed on The Nasdaq Stock Market LLC under the symbol MLAB, and it regularly submits reports and disclosures that detail its operations, governance, and financial condition.
Through this page, users can review current and historical filings such as Form 8-K reports, which Mesa uses to announce material events. Recent 8-K filings have covered topics including quarterly financial results, the creation of direct financial obligations under its credit facility, and the settlement of outstanding convertible notes. These filings often reference accompanying press releases that provide additional narrative and financial tables.
Investors can also find proxy materials, such as the company’s definitive proxy statement (DEF 14A). This document outlines items for shareholder vote at the annual meeting, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and amendments to equity incentive plans. The proxy statement also describes Mesa’s board committees and aspects of its executive compensation framework.
In addition to these documents, Mesa’s SEC filings reference its credit facility, leverage metrics, and other capital structure details, giving readers insight into how the company finances its operations and manages debt. Stock Titan’s interface surfaces these filings with AI-powered summaries that help explain key sections, making it easier to understand complex disclosures without reading every page.
Users interested in MLAB can use this page to monitor new filings as they are posted to EDGAR, review past disclosures, and better understand the regulatory and governance context surrounding Mesa’s life science tools and quality control business.
Form 4 filing – Mesa Laboratories Inc. (MLAB)
President & CEO Gary M. Owens reported two transactions dated 06/21/2025: (1) the conversion of 3,301 Restricted Stock Units (Code “M”) into common stock at a referenced price of $95.82 per share, and (2) the withholding of 1,445 shares for tax purposes (Code “F”) at the same price. Following these transactions, Owens’ direct ownership rose from an implied 50,721 shares to 52,577 shares, a net increase of 1,856 shares. The RSUs originated from a grant that vests one-third annually (2024-2026). No open-market purchases or sales were disclosed; all activity relates to equity compensation.
The filing is routine, indicating continued equity alignment but limited new cash investment by the insider.
Mesa Laboratories Inc. (MLAB) – Form 4 insider transaction dated 06/18/2025
Senior Vice-President of Operations Brian D. Archbold reported the automatic conversion of 2,556 restricted stock units (RSUs) into common shares (Transaction Code M) at a reference price of $92.99 per share. To cover tax obligations, he simultaneously disposed of 1,166 shares via a tax-withholding transaction (Code F) at the same price.
Post-transaction direct holdings changed as follows:
- Common stock: 1,948 shares now held directly (down from 3,114 immediately after the RSU conversion).
- Unvested/remaining RSUs: 4,960 units retained, scheduled to vest one-third on 18 June 2025 and on each of the next two anniversaries.
The activity reflects routine equity compensation vesting rather than an open-market purchase or sale; no cash was exchanged for the share acquisition portion.
Mesa Laboratories, Inc. (MLAB) – Form 4 insider transaction filed 06/20/2025
CFO John Sakys reported activity dated 06/18/2025 involving the exercise and settlement of restricted stock units (RSUs) and related tax withholding.
- RSU exercise (Code M): 2,840 common shares were issued upon vesting of previously granted RSUs. Each RSU converts 1-for-1 into common stock.
- Tax withholding (Code F): 1,243 of the newly issued shares were automatically withheld at a reference price of $92.99 to satisfy tax obligations.
After the transactions, Sakys’ direct beneficial ownership changed from 12,865 shares to 14,462 shares, a net increase of 1,597 shares (≈12.4%).
The RSU award vests in three equal annual installments beginning 06/18/2025, providing future potential share deliveries on the next two anniversary dates.
No derivative positions remain other than 5,511 unvested RSUs outstanding.
Because the share acquisition arose from planned equity compensation rather than open-market buying, the filing signals routine ownership growth rather than an active market purchase, though the net increase modestly aligns the CFO’s incentives with shareholders.